AstraZeneca and Vanderbilt University Partner to Develop Drugs for Major Brain Disorders
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 1 (Table of Contents)
Published: 22 Jan-2013
DOI: 10.3833/pdr.v2013.i1.1875 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Continuing its virtual CNS R&D strategy, AstraZeneca has formed a research partnership with Vanderbilt University to identify drug candidates for the treatment of psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS